World Financial News Network continues to recommend Endo-Bronchial Technologies

Share Article

Dr. Joseph de Beauchamp of World Financial News Network started coverage and gives favorable analysis to Endo-Bronchial Technologies as a company that helps people with emphysema and COPD.

WFNN's consistently outperforms established industry benchmark indicators. Based on in-depth research and analysis, their analysts recommend securities worldwide showing the highest probability for stock price appreciation. With constant vigil, WFNN looks for economic opportunities in the private and public company sectors.

Dr. Joseph de Beauchamp, WFNN's Chief Independent Analyst, said, " World Financial News Network see InterWest Partners, Investor Growth Capital, Three Arch Partners, New Enterprise Associates, Versant Ventures, Sprout Group, and Guidant Investment deciding to invest in this new technology: lower cost and risk device. By developing devices to reduce air leaks and bleeding following lung surgery for patients with emphysema and chronic bronchitis, we see the company helping millions. Using this valve helps patients avoid surgery. We see the stock moving up from par value, this is a private company at this time, to ten fold in the next two years. With the company thinking up new ways to use this device, we see this company in high growth for the next several years. Numbers below show projection into the future several years and do not indicate current finances of the company."

For brief information of this new, dynamic company, examine: displaying in the search engine section.

About WFNN: World Financial News Network provides a unique blend of data, timely information and today's technologies to assist with up-to-the-minute investment and economic values on markets and investments around the world.

About Endo-Bronchial Technologies

Endo-Bronchial Technologies (EBT) started to develop an endo-bronchial medical technology. EBT plans to designs and sell devices that treat patients with emphysema and COPD. Several venture backed expansion-stage companies formed capital pools to invest in this less invasive approach to blocking airflow to the diseased portion of the lungs in emphysema patients. Without surgery, this method shows promise for viable treatment option for patients with severe emphysema. The clinical outcomes and safety of the endo-bronchial treatment/ blockage approach continue in final phase of human clinical trials in the US. EBT believes that they hold patients for a lower cost and more effective delivery of this treatment.

Endo-Bronchial Technologies

1425 4th Avenue Suite 505

Seattle, Washington 98101


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joseph De Beauchamp
Email >